6533b821fe1ef96bd127b95c

RESEARCH PRODUCT

Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)

Jean-yves ReginsterPhilip C. CalderMila VlaskovskaEtienne CavalierClaudio FranceschiNicholas R FuggleIslene Araujo De CarvalhoPierre MiossecFrancis BerenbaumAndrea LaslopThierry ThomasRené RizzoliElaine M. DennisonVincenzo CastronovoCyrus CooperAna M. ValdesŞAnsın TüzünMaria Luisa BrandiNicola VeroneseEmmanuel BiverLaure B. BindelsAntonio Cherubini

subject

0301 basic medicineAgingmedicine.medical_specialtyOsteoporosisPsychological interventionOsteoarthritisGut microbiotaGut floraDysbiosis; Gut microbiota; Inflammaging; Modern diet; Obesity; OsteoarthritisBiochemistry03 medical and health sciences0302 clinical medicineOsteoarthritismedicineAnimalsHumansMusculoskeletal DiseasesObesityModern dietIntensive care medicineMolecular BiologySocieties MedicalInflammationbiologybusiness.industrymedicine.diseasebiology.organism_classificationObesityInflammagingDysbiosiInflammaging ObesityGastrointestinal MicrobiomeEurope030104 developmental biologyNeurologyOsteoporosisDysbiosisObservational studyOsteoarthritiMetabolic syndromebusinessDysbiosis030217 neurology & neurosurgeryBiotechnology

description

Berenbaum, Francis/0000-0001-8252-7815; Dennison, Elaine/0000-0002-3048-4961; Bindels, Laure B./0000-0003-3747-3234; Cooper, Cyrus/0000-0003-3510-0709 WOS:000491638300002 PubMed ID: 31437484 The prevalence of osteoarthritis (OA) increases not only because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and diets low in fiber and rich in sugar and saturated fats, which promote chronic low-grade inflammation and obesity. Adverse alterations of the gut microbiota (GMB) composition, called microbial dysbiosis, may favor metabolic syndrome and inflammaging, two important components of OA onset and evolution. Considering the burden of OA and the need to define preventive and therapeutic interventions targeting the modifiable components of OA, an expert working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) to review the potential contribution of GMB to OA. Such a contribution is supported by observational or dietary intervention studies in animal models of OA and in humans. In addition, several well-recognized risk factors of OA interact with GMB. Lastly, GMB is a critical determinant of drug metabolism and bioavailability and may influence the response to OA medications. Further research targeting GMB or its metabolites is needed to move the field of OA from symptomatic management to individualized interventions targeting its pathogenesis. European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) under WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging The meeting was funded by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) under the auspices of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging.

yearjournalcountryeditionlanguage
2019-01-01
10.1016/j.arr.2019.100946https://hdl.handle.net/20.500.12831/759